Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04484623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04484623 · ClinicalTrials.gov record · last posted 2026-06-12

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Study acronym: DREAMM 8
StatusActive, Not Recruiting
PhasePhase 3
Started2020-10-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Amendment record 21 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 21 times since 2020-07-21; most recent amendment 2026-05-25. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-01-27
Status change Recruiting→Active, Not Recruitingv19
2020-10-20
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT04484623
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 302 participants
Start Date 2020-10-01
Primary Completion 2024-01-29 (estimated)
Study Completion 2029-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-12